ID   CA46
AC   CVCL_1101
SY   CA-46; CA 46
DR   BTO; BTO:0000789
DR   CLO; CLO_0002168
DR   EFO; EFO_0002124
DR   CLDB; cl608
DR   CLDB; cl609
DR   CLDB; cl610
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1648
DR   BCRC; 60511
DR   BioSample; SAMN03473116
DR   BioSample; SAMN10987878
DR   cancercelllines; CVCL_1101
DR   CCRID; 1101HUM-PUMC000366
DR   CCRID; 4201HUM-CCTCC00098
DR   CCTCC; GDC0098
DR   Cell_Model_Passport; SIDM00907
DR   ChEMBL-Cells; CHEMBL3308488
DR   ChEMBL-Targets; CHEMBL612566
DR   CLS; 305082
DR   Cosmic; 687837
DR   Cosmic; 850210
DR   Cosmic; 910703
DR   Cosmic; 931101
DR   Cosmic; 1086325
DR   Cosmic; 1818340
DR   Cosmic; 2297029
DR   Cosmic; 2808223
DR   Cosmic; 2814536
DR   Cosmic-CLP; 910703
DR   DepMap; ACH-000440
DR   DSMZ; ACC-73
DR   DSMZCellDive; ACC-73
DR   ECACC; 95010509
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 910703
DR   GEO; GSM119505
DR   GEO; GSM886900
DR   GEO; GSM887965
DR   GEO; GSM1177977
DR   GEO; GSM1177978
DR   GEO; GSM1669641
DR   IARC_TP53; 7395
DR   ICLC; HTL97007
DR   IGRhCellID; CA46
DR   IZSLER; BS TCL 159
DR   LiGeA; CCLE_534
DR   LINCS_LDP; LCL-2017
DR   Lonza; 439
DR   NCBI_Iran; C106
DR   PharmacoDB; CA46_159_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1101
DR   PubChem_Cell_line; CVCL_1101
DR   Wikidata; Q54808297
RX   PubMed=1325212;
RX   PubMed=2052620;
RX   PubMed=3026973;
RX   PubMed=3080238;
RX   PubMed=3921823;
RX   PubMed=6243721;
RX   PubMed=6243722;
RX   PubMed=6265077;
RX   PubMed=6286763;
RX   PubMed=8220424;
RX   PubMed=8316623;
RX   PubMed=8344493;
RX   PubMed=8402660;
RX   PubMed=8515068;
RX   PubMed=8558920;
RX   PubMed=9192833;
RX   PubMed=9473234;
RX   PubMed=9643977;
RX   PubMed=9787181;
RX   PubMed=9973220;
RX   PubMed=10567774;
RX   PubMed=11587216;
RX   PubMed=12145705;
RX   PubMed=16960149;
RX   PubMed=17254797;
RX   PubMed=19220422;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=22885699;
RX   PubMed=24590883;
RX   PubMed=25355872;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: MYC genetic alteration cell panel (ATCC TCP-1035).
CC   Characteristics: Produces IgM kappa (ATCC=CRL-1648).
CC   Virology: EBV-negative.
CC   Doubling time: 21 hours (PubMed=8402660); ~16 hours (ATCC=CRL-1648); ~35 hours (DSMZ=ACC-73).
CC   HLA typing: A*26:03,26:03; B*27:04,27:04; C*12:02,12:02; DQA1*01:03,01:03; DQB1*06:01,06:01; DRB1*08:03,08:03 (PubMed=25960936).
CC   HLA typing: A*02:01,24:02; B*27:04,27:04; C*12:02,12:02; DQA1*01:03,01:03; DQB1*05:03,06:01; DRB1*08:03,08:03 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=3921823; PubMed=9643977; PubMed=11587216).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=8344493; PubMed=8402660; PubMed=19220422; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=33.18%; Native American=0.85%; East Asian, North=7.55%; East Asian, South=35.68%; South Asian=0%; European, North=9.41%; European, South=13.32% (PubMed=30894373).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; DSMZ; PubMed=17254797; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11 (PubMed=17254797)
ST   CSF1PO: 10,12 (ATCC; CCRID; Cosmic-CLP; DSMZ; PubMed=25877200)
ST   D13S317: 8,12
ST   D16S539: 11,12
ST   D18S51: 13,16
ST   D19S433: 15.2 (ATCC; CCRID)
ST   D19S433: 16 (DSMZ)
ST   D21S11: 27,28 (PubMed=17254797)
ST   D21S11: 28,29 (ATCC; CCRID; DSMZ; PubMed=25877200)
ST   D2S1338: 20,22
ST   D3S1358: 16,18
ST   D5S818: 13
ST   D7S820: 11,12
ST   D8S1179: 15 (ATCC; CCRID; DSMZ; PubMed=25877200)
ST   D8S1179: 16 (PubMed=17254797)
ST   FGA: 19,23
ST   Penta D: 12,13
ST   Penta E: 5,11
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 15,16
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 45
//
RX   PubMed=1325212; DOI=10.1182/blood.V80.5.1289.1289;
RA   Benjamin D., Knobloch T.J., Dayton M.A.;
RT   "Human B-cell interleukin-10: B-cell lines derived from patients with
RT   acquired immunodeficiency syndrome and Burkitt's lymphoma
RT   constitutively secrete large quantities of interleukin-10.";
RL   Blood 80:1289-1298(1992).
//
RX   PubMed=2052620; DOI=10.1073/pnas.88.12.5413;
RA   Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A.,
RA   Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.;
RT   "p53 mutations in human lymphoid malignancies: association with
RT   Burkitt lymphoma and chronic lymphocytic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991).
//
RX   PubMed=3026973; DOI=10.1002/ijc.2910390215;
RA   Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.;
RT   "Expression of B-cell-specific markers in different Burkitt lymphoma
RT   subgroups.";
RL   Int. J. Cancer 39:211-218(1987).
//
RX   PubMed=3080238;
RA   Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.;
RT   "Expression of surface antigens during the cell cycle in different
RT   growth phases of American and African Burkitt's lymphoma cell lines.";
RL   Cancer Res. 46:1182-1188(1986).
//
RX   PubMed=3921823; DOI=10.1128/mcb.5.3.501-509.1985;
RA   Showe L.C., Ballantine M., Nishikura K., Erikson J., Kaji H.,
RA   Croce C.M.;
RT   "Cloning and sequencing of a c-myc oncogene in a Burkitt's lymphoma
RT   cell line that is translocated to a germ line alpha switch region.";
RL   Mol. Cell. Biol. 5:501-509(1985).
//
RX   PubMed=6243721; DOI=10.1093/jnci/64.3.465;
RA   Magrath I.T., Pizzo P.A., Whang-Peng J., Douglass E.C., Alabaster O.,
RA   Gerber P., Freeman C.B., Novikovs L.;
RT   "Characterization of lymphoma-derived cell lines: comparison of cell
RT   lines positive and negative for Epstein-Barr virus nuclear antigen. I.
RT   Physical, cytogenetic, and growth characteristics.";
RL   J. Natl. Cancer Inst. 64:465-476(1980).
//
RX   PubMed=6243722; DOI=10.1093/jnci/64.3.477;
RA   Magrath I.T., Freeman C.B., Pizzo P.A., Gadek J., Jaffe E.S.,
RA   Santaella M., Hammer C., Frank M., Reaman G., Novikovs L.;
RT   "Characterization of lymphoma-derived cell lines: comparison of cell
RT   lines positive and negative for Epstein-Barr virus nuclear antigen.
RT   II. Surface markers.";
RL   J. Natl. Cancer Inst. 64:477-483(1980).
//
RX   PubMed=6265077;
RA   Pizzo P.A., Chattopadhyay S.K., Magrath I.T., Del Giacco E.,
RA   Sherrick D., Gray T.;
RT   "Examination of Epstein-Barr virus and C-type proviral sequences in
RT   American and African lymphomas and derivative cell lines.";
RL   Cancer Res. 41:3165-3171(1981).
//
RX   PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336;
RA   Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D.,
RA   Parsons R.G.;
RT   "Immunoglobulin secretion by cell lines derived from African and
RT   American undifferentiated lymphomas of Burkitt's and non-Burkitt's
RT   type.";
RL   J. Immunol. 129:1336-1342(1982).
//
RX   PubMed=8220424; DOI=10.1038/ng0993-56;
RA   Bhatia K.G., Huppi K., Spangler G., Siwarski D., Iyer R., Magrath I.T.;
RT   "Point mutations in the c-Myc transactivation domain are common in
RT   Burkitt's lymphoma and mouse plasmacytomas.";
RL   Nat. Genet. 5:56-61(1993).
//
RX   PubMed=8316623; DOI=10.2307/3578190;
RA   Evans H.H., Ricanati M., Horng M.-F., Jiang Q.-Y., Mencl J.,
RA   Olive P.L.;
RT   "DNA double-strand break rejoining deficiency in TK6 and other human
RT   B-lymphoblast cell lines.";
RL   Radiat. Res. 134:307-315(1993).
//
RX   PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493;
RA   Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R.,
RA   Magrath I.T.;
RT   "Hemi- or homozygosity: a requirement for some but not other p53
RT   mutant proteins to accumulate and exert a pathogenetic effect.";
RL   FASEB J. 7:951-956(1993).
//
RX   PubMed=8402660;
RA   O'Connor P.M., Jackman J., Jondle D., Bhatia K.G., Magrath I.T.,
RA   Kohn K.W.;
RT   "Role of the p53 tumor suppressor gene in cell cycle arrest and
RT   radiosensitivity of Burkitt's lymphoma cell lines.";
RL   Cancer Res. 53:4776-4780(1993).
//
RX   PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=9192833;
RA   Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S.,
RA   Pike S.E., Gupta G., Magrath I.T., Tosato G.;
RT   "Role of the p53 tumor suppressor gene in the tumorigenicity of
RT   Burkitt's lymphoma cells.";
RL   Cancer Res. 57:2508-2515(1997).
//
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
//
RX   PubMed=9643977; DOI=10.1016/S0378-1119(98)00104-8;
RA   Khaira P., James C.D., Leffak M.;
RT   "Amplification of the translocated c-myc genes in three Burkitt
RT   lymphoma cell lines.";
RL   Gene 211:101-108(1998).
//
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
//
RX   PubMed=9973220;
RA   Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G.,
RA   Magrath I.T., Bhatia K.G.;
RT   "Bax is frequently compromised in Burkitt's lymphomas with
RT   irreversible resistance to Fas-induced apoptosis.";
RL   Cancer Res. 59:696-703(1999).
//
RX   PubMed=10567774; DOI=10.1159/000007237;
RA   Fan S.-J., Duba D.E., O'Connor P.M.;
RT   "Cellular effects of olomoucine in human lymphoma cells differing in
RT   p53 function.";
RL   Chemotherapy 45:437-445(1999).
//
RX   PubMed=11587216; DOI=10.1038/sj.leu.2402281;
RA   Zimonjic D.B., Keck-Waggoner C.L., Popescu N.C.;
RT   "Novel genomic imbalances and chromosome translocations involving
RT   c-myc gene in Burkitt's lymphoma.";
RL   Leukemia 15:1582-1588(2001).
//
RX   PubMed=12145705; DOI=10.1038/sj.leu.2402519;
RA   Langerak A.W., Moreau E., van Gastel-Mol E.J., van der Burg M.,
RA   van Dongen J.J.M.;
RT   "Detection of clonal EBV episomes in lymphoproliferations as a
RT   diagnostic tool.";
RL   Leukemia 16:1572-1573(2002).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001;
RA   Azari S., Ahmadi N., Tehrani M.J., Shokri F.;
RT   "Profiling and authentication of human cell lines using short tandem
RT   repeat (STR) loci: report from the National Cell Bank of Iran.";
RL   Biologicals 35:195-202(2007).
//
RX   PubMed=19220422; DOI=10.1111/j.1600-0609.2009.01211.x;
RA   Kamihira S., Terada C., Sasaki D., Yanagihara K., Tsukasaki K.,
RA   Hasegawa H., Yamada Y.;
RT   "Aberrant p53 protein expression and function in a panel of
RT   hematopoietic cell lines with different p53 mutations.";
RL   Eur. J. Haematol. 82:301-307(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22885699; DOI=10.1038/nature11378;
RA   Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L.,
RA   Wright G., Shaffer A.L. III, Hodson D.J., Buras E., Liu X.-L., Powell J.I.,
RA   Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W.,
RA   Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.;
RT   "Burkitt lymphoma pathogenesis and therapeutic targets from structural
RT   and functional genomics.";
RL   Nature 490:116-120(2012).
//
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Murga Penas E.-M., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//